GeoVax is a clinical-stage company developing vaccines against infectious diseases and cancer using a novel Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within the person receiving the vaccine. The production of VLPs in vivo mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector. GeoVax’s development programs are focused on preventive vaccines against HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against chronic Hepatitis B infections and cancers.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Preventive & Therapeutic HIV Vaccine
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):